We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
French drug giant Sanofi will terminate its licensing agreement with Auvi-Q developer kaléo later this year, returning U.S. and Canadian rights to the epinephrine injection to the company. Read More
The study’s results demonstrated that patients treated with Zilretta experienced a 50 percent reduction in pain from baseline against placebo. Read More
The FDA is offering more information on trial designs for sponsors developing therapies to treat allergic and nonallergic rhinitis and anthrax exposure. Read More